Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | SSTR1 | P30872 | 5/20 | 0.54 |
| ▸ | SSTR4 | P31391 | 5/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14263120 | 0.92 | SSTR4 (0.51) | SIGMAR1SSTR1SSTR4EPHX2CYP2C9 | |
| SCHEMBL4982505 | 0.83 | DRD4 (0.51) | SSTR1SSTR4EPHX2P2RX7DRD4 | |
| SCHEMBL16269299 | 0.82 | KDM4E (0.55) | SIGMAR1SSTR1SSTR4EPHX2CYP2C9 | |
| SCHEMBL4982989 | 0.81 | NPC1 (0.57) | SIGMAR1SSTR1SSTR4EPHX2P2RX7 | |
| SCHEMBL16269121 | 0.81 | P2RX7 (0.53) | SIGMAR1EPHX2CYP2C9CYP3A4P2RX7 | |
| SCHEMBL4980641 | 0.80 | MCHR1 (0.63) | SIGMAR1SSTR1SSTR4CYP3A4POLB | |
| SCHEMBL16269460 | 0.79 | EPHX2 (0.56) | EPHX2CYP2C9CYP3A4P2RX7KDM4E | |
| SCHEMBL14263114 | 0.78 | DRD4 (0.73) | EPHX2POLBDRD4 | |
| SCHEMBL4979582 | 0.78 | SLC6A5 (0.59) | EPHX2DRD4 | |
| SCHEMBL4981131 | 0.78 | SSTR4 (0.59) | SSTR1SSTR4EPHX2TSHRDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | HRH3, HRH1, HRH4 | SIGMAR1 93/4885SSTR1 291/4885SSTR4 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.